K G Lim, A Sumera, S P Venkateswaran, I A S Burud, N I J Albazah
{"title":"B-cell lymphoma research in Malaysia - A narrative review.","authors":"K G Lim, A Sumera, S P Venkateswaran, I A S Burud, N I J Albazah","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Lymphomas are a diverse group of malignant proliferations that arise as discrete tissue masses. The most widely accepted taxonomy for lymphoma is the World Health Organization classification of tumours of haematopoietic and lymphoid tissues, the 5th edition of which was released in June 2022. Most (85% to 90%) lymphoid neoplasms are of B cell origin. Mature B-cell neoplasms are a heterogeneous group of malignancies with similar disease courses and treatment paradigms. This review focuses on the various mature B-cell lymphomas in Malaysia, including Hodgkin lymphoma. A literature search was performed in various bibliographic databases. A total of 64 papers were included in this review. We found 15 papers on Hodgkin lymphoma, 14 on follicular lymphoma, 12 on Burkitt lymphoma, 5 on mucosa-associated lymphoid tissue (MALT) lymphoma, 4 on plasmablastic lymphoma, 3 on mantle cell lymphoma, 1 each on primary mediastinal large B-cell lymphoma, B-lymphoblastic lymphoma, and 3 on other unspecified B-cell lymphomas. The site, age, distribution, prognostic markers, and the various subclassification of B cell lymphomas were studied from these papers. Prognostic genetic markers in B-cell lymphomas include C-MYC, BCL2 and BCL6 as they are the most prevalent mutations in this condition. Anecdotal outcomes range from rapid fatality to unexplained spontaneous remission. This review adds to the existing literature on lymphoma in Malaysia by compiling the evidence that may lead to further research on the diagnosis and treatment of lymphoma in Malaysia and worldwide.</p>","PeriodicalId":48723,"journal":{"name":"Malaysian Journal of Pathology","volume":"46 1","pages":"11-20"},"PeriodicalIF":0.6000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaysian Journal of Pathology","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Lymphomas are a diverse group of malignant proliferations that arise as discrete tissue masses. The most widely accepted taxonomy for lymphoma is the World Health Organization classification of tumours of haematopoietic and lymphoid tissues, the 5th edition of which was released in June 2022. Most (85% to 90%) lymphoid neoplasms are of B cell origin. Mature B-cell neoplasms are a heterogeneous group of malignancies with similar disease courses and treatment paradigms. This review focuses on the various mature B-cell lymphomas in Malaysia, including Hodgkin lymphoma. A literature search was performed in various bibliographic databases. A total of 64 papers were included in this review. We found 15 papers on Hodgkin lymphoma, 14 on follicular lymphoma, 12 on Burkitt lymphoma, 5 on mucosa-associated lymphoid tissue (MALT) lymphoma, 4 on plasmablastic lymphoma, 3 on mantle cell lymphoma, 1 each on primary mediastinal large B-cell lymphoma, B-lymphoblastic lymphoma, and 3 on other unspecified B-cell lymphomas. The site, age, distribution, prognostic markers, and the various subclassification of B cell lymphomas were studied from these papers. Prognostic genetic markers in B-cell lymphomas include C-MYC, BCL2 and BCL6 as they are the most prevalent mutations in this condition. Anecdotal outcomes range from rapid fatality to unexplained spontaneous remission. This review adds to the existing literature on lymphoma in Malaysia by compiling the evidence that may lead to further research on the diagnosis and treatment of lymphoma in Malaysia and worldwide.
淋巴瘤是一种以离散组织肿块形式出现的恶性增生，种类繁多。最广为接受的淋巴瘤分类法是世界卫生组织的造血和淋巴组织肿瘤分类法，该分类法的第五版已于 2022 年 6 月发布。大多数（85% 至 90%）淋巴肿瘤起源于 B 细胞。成熟 B 细胞肿瘤是一组异质性恶性肿瘤，具有相似的病程和治疗模式。本综述主要介绍马来西亚的各种成熟B细胞淋巴瘤，包括霍奇金淋巴瘤。我们在各种文献数据库中进行了文献检索。本综述共收录了 64 篇论文。其中霍奇金淋巴瘤15篇，滤泡淋巴瘤14篇，伯基特淋巴瘤12篇，粘膜相关淋巴组织（MALT）淋巴瘤5篇，浆细胞淋巴瘤4篇，套细胞淋巴瘤3篇，原发性纵隔大B细胞淋巴瘤和B淋巴母细胞淋巴瘤各1篇，其他不明B细胞淋巴瘤3篇。这些论文对 B 细胞淋巴瘤的发病部位、年龄、分布、预后标志物和各种亚分类进行了研究。B细胞淋巴瘤的预后遗传标记包括C-MYC、BCL2和BCL6，因为它们是这种疾病中最常见的突变。轶事结果从迅速死亡到原因不明的自发缓解不等。本综述汇集了有关马来西亚淋巴瘤的证据，为现有文献增添了新的内容，有助于进一步研究马来西亚及全球淋巴瘤的诊断和治疗。
期刊介绍：
The Malaysian Journal of Pathology is the official journal of the College of Pathologists, Academy of Medicine Malaysia. The primary purpose of The Journal is to publish the results of study and research in Pathology, especially those that have particular relevance to human disease occurring in Malaysia and other countries in this region. The term PATHOLOGY will be interpreted in its broadest sense to include Chemical Pathology, Cytology, Experimental Pathology, Forensic Pathology, Haematology, Histopathology, Immunology, Medical Microbiology and Parasitology. The Journal aims to bring under one cover publications of regional interest embracing the various sub-specialities of Pathology. It is expected that the articles published would be of value not only to pathologists, but also to medical practitioners in search of a scientific basis for the problems encountered in their practice, and to those with an interest in diseases which occur in the tropics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
